KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Average (2018 - 2025)

Vir Biotechnology's Equity Average history spans 8 years, with the latest figure at $780.7 million for Q4 2025.

  • For Q4 2025, Equity Average fell 34.7% year-over-year to $780.7 million; the TTM value through Dec 2025 reached $780.7 million, down 34.7%, while the annual FY2025 figure was $957.8 million, 30.1% down from the prior year.
  • Equity Average for Q4 2025 was $780.7 million at Vir Biotechnology, down from $871.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $2.1 billion in Q4 2022 and bottomed at $683.9 million in Q1 2021.
  • The 5-year median for Equity Average is $1.4 billion (2024), against an average of $1.4 billion.
  • The largest annual shift saw Equity Average skyrocketed 184.74% in 2022 before it tumbled 34.81% in 2025.
  • A 5-year view of Equity Average shows it stood at $1.2 billion in 2021, then skyrocketed by 83.17% to $2.1 billion in 2022, then decreased by 22.77% to $1.6 billion in 2023, then fell by 26.77% to $1.2 billion in 2024, then plummeted by 34.7% to $780.7 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Equity Average are $780.7 million (Q4 2025), $871.8 million (Q3 2025), and $995.6 million (Q2 2025).